Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8819228 | 0.87 | ATM (0.45) | ATMLMNAMAPTHTTKDM4E | |
| SCHEMBL3753188 | 0.83 | XDH (0.44) | ATMLMNAMAPTHTTKDM4E | |
| SCHEMBL8818334 | 0.81 | ATM (0.49) | ATMLMNAMAPTHTTKDM4E | |
| SCHEMBL711918 | 0.81 | KDM4E (0.39) | ATMLMNAMAPTHTTKDM4E | |
| SCHEMBL6587304 | 0.81 | ERN1 (0.43) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL9330422 | 0.81 | ATM (0.48) | ATMLMNAMAPTHTTKDM4E | |
| SCHEMBL499545 | 0.78 | ATM (0.46) | ATMLMNAMAPTHTTKDM4E | |
| SCHEMBL11836656 | 0.78 | ATM (0.58) | ATMLMNAMAPTHTTKDM4E | |
| SCHEMBL9607486 | 0.78 | ATM (0.46) | ATMLMNAMAPTHTTKDM4E | |
| SCHEMBL9330931 | 0.78 | ATM (0.51) | ATMLMNAMAPTHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| CN-101528690-A | Isoindoline derivatives for the treatment of arrhythmias | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | ATM 4357/4885LMNA 228/4885MAPT 4504/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | ATM 2001/4885LMNA 461/4885MAPT 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.